Oracle Argus Safety is a multivigilance solution for processing, analysing, and reporting adverse event cases originating in pre- and post-market drugs, biologics, vaccines, devices, and combination products. It is a 360-degree multivigilance software system that was designed to solve the pharmaceutical industry’s biggest regulatory challenges.
Oracle Argus Safety allows managing adverse event cases more accurately and more efficiently whilst ensuring regulatory compliance, helping Life Sciences companies to satisfy their growing needs.
Oracle Argus Safety is currently used worldwide by a wide range of Life Sciences companies such as:
- Pharmaceutical
- Biotech
- CRO (Clinical Research organisation)
- Medical device manufacturers
Scalable and efficient, Oracle Argus allows continuous evaluation of the risk-benefit profile of products throughout clinical and post-marketing development in accordance with Good Clinical Practice (GCP) and Good Pharmacovigilance Practice (GVP). Argus is a reliable solution that offers efficient reporting functions and guarantees with regulations and standards on the national and international levels.
In April 2021, Oracle released a new patch 8.2.3 that addressed new important regulatory compliance requirements, functional enhancements, and technology platform currency.
In this white paper, we will share the details of the Oracle Argus Release 8.2.3 and analyse the benefits for Life Sciences companies of moving from outdated legacy systems to Argus or upgrading their Argus platform to this new release.
